About RedHill

RedHill Biopharma Ltd. (NASDAQ: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases.

RedHill promotes three gastrointestinal products in the U.S.:

Movantik® (naloxegol)  

Talicia® (omeprazole magnesium, amoxicillin and rifabutin)

Aemcolo® (rifamycin)

RedHill's current product pipeline includes:

Opaganib (Yeliva®, ABC294640) - An orally-administered, first-in-class SK2 selective inhibitor, targeting multiple oncology, inflammatory and gastrointestinal indications, with an ongoing Phase 2a study for cholangiocarcinoma and a development program for COVID-19.

RHB-204 - An oral combination therapy with a Phase 3 study for nontuberculous mycobacteria (NTM) infections.

RHB-104 - An oral combination therapy with positive top-line results from a first Phase 3 study for Crohn's disease.

RHB-102 (Bekinda®) - A once-daily oral pill formulation of ondansetron with positive results from a Phase 3 study in acute gastroenteritis and gastritis and positive results from a Phase 2 study in IBS-D.

RHB-107 - a Phase 2-stage serine protease inhibitor with a planned Phase 2/3 study in symptomatic COVID-19 and targeting multiple other cancer and inflammatory gastrointestinal diseases.

RHB-106 - A proprietary, flavorless, odorless, solid oral encapsulated formulation for the preparation and cleansing of the gastrointestinal tract.

Learn more about our COVID-19 response